Sitagliptin, Glipizide Comparable In Type 2 Diabetes Patients With ESRD.
MedPage Today 
(11/16, Bankhead) reports, "Two oral hypoglycemic drugs achieved similar diabetes control in patients with type 2 diabetes and end-stage renal disease (ESRD), but sitagliptin (Januvia) did so without weight gain," according to research presented at the American Society of Nephrology's annual meeting. "About 30% of patients achieved a hemoglobin A1c (HbA1c) <6.5% after a year of treatment with sitagliptin or glipizide, and 42% to 47% of patients reached an HbA1c goal of <7.0% with either drug, a nonsignificant difference," while "the mean estimated glomerular filtration rate (eGFR) declined by 3 to 4 mL/min/1.73 m2 in both treatment groups, and the urinary albumin-creatinine ratio did not differ significantly at any time during the trial." MedPage Today notes, however, that "patients in the glipizide arm had a tendency to gain weight, whereas those treated with sitagliptin had a small decrease in weight."
(11/16, Bankhead) reports, "Two oral hypoglycemic drugs achieved similar diabetes control in patients with type 2 diabetes and end-stage renal disease (ESRD), but sitagliptin (Januvia) did so without weight gain," according to research presented at the American Society of Nephrology's annual meeting. "About 30% of patients achieved a hemoglobin A1c (HbA1c) <6.5% after a year of treatment with sitagliptin or glipizide, and 42% to 47% of patients reached an HbA1c goal of <7.0% with either drug, a nonsignificant difference," while "the mean estimated glomerular filtration rate (eGFR) declined by 3 to 4 mL/min/1.73 m2 in both treatment groups, and the urinary albumin-creatinine ratio did not differ significantly at any time during the trial." MedPage Today notes, however, that "patients in the glipizide arm had a tendency to gain weight, whereas those treated with sitagliptin had a small decrease in weight."
No comments:
Post a Comment